Literature DB >> 7105381

In vitro degradation of L-phenylalanine mustard (L-PAM).

T L Evans, S Y Chang, D S Alberts, I G Sipes, K Brendel.   

Abstract

L-Phenylalanine mustard (L-PAM), a bis-choroethylamine, is an important drug in the treatment of multiple myeloma and ovarian cancer. It undergoes rapid hydrolysis in vitro and in vivo, forming the mono-and dihydroxy degradation products. L-PAM's first-order disappearance rate in a phosphate-buffered solution did not differ statistically according to the presence or absence of activated rat liver microsomal enzymes. Furthermore, L-PAM's disappearance rate in a rat whole liver perfusion system was not greater than its hydrolysis rate in water. In vitro plasma recovery studies showed that up to 85% of the 14C L-PAM drug equivalents could be recovered as the parent compound and the mono- and dihydroxy degradation products. Thus, L-PAM in in vitro degradation was similar qualitatively and quantitatively to its reported in vivo degradation in animals and man. It is concluded that L-PAM does not undergo important, active in vivo metabolism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7105381     DOI: 10.1007/BF00255479

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  Inhibition of gluconeogenesis in the isolated perfused rat liver by -phenylalkanoic acids.

Authors:  L González de Galdeano; R Bressler; K Brendel
Journal:  J Biol Chem       Date:  1973-04-10       Impact factor: 5.157

2.  The stability of melphalan in the presence of chloride ion.

Authors:  S Y Chang; T L Evans; D S Alberts
Journal:  J Pharm Pharmacol       Date:  1979-12       Impact factor: 3.765

3.  Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease.

Authors:  M H Tattersall; M Jarman; E S Newlands; L Holyhead; R A Milstead; A Weinberg
Journal:  Eur J Cancer       Date:  1978-05       Impact factor: 9.162

4.  The stability of L-phenylalanine mustard in bile.

Authors:  S Y Chang; T L Evans; D S Alberts; I G Sipes
Journal:  Life Sci       Date:  1978-10-23       Impact factor: 5.037

5.  Biliary excretion of melphalan by control and anuric rats.

Authors:  K H Byington; C C Bowe; D S McKinsey
Journal:  Biochem Pharmacol       Date:  1980-09-15       Impact factor: 5.858

6.  A method for the measurement of L-phenylalanine mustard in the mouse and dog by high-pressure liquid chromatography.

Authors:  R L Furner; L B Mellett; R K Brown; G Duncan
Journal:  Drug Metab Dispos       Date:  1976 Nov-Dec       Impact factor: 3.922

7.  Pharmacokinetics of the absorption, distribution, and elimination of melphalan in the dog.

Authors:  R L Furner; R K Brown; G Duncan
Journal:  Cancer Treat Rep       Date:  1977-12

8.  Oral melphalan kinetics.

Authors:  D S Alberts; S Y Chang; H S Chen; T L Evans; T E Moon
Journal:  Clin Pharmacol Ther       Date:  1979-12       Impact factor: 6.875

9.  High-pressure liquid chromatographic analysis of melphalan in plasma.

Authors:  S Y Chang; D S Alberts; L R Melnick; P D Walson; S E Salmon
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

10.  Hydrolysis and protein binding of melphalan.

Authors:  S Y Chang; D S Alberts; D Farquhar; L R Melnick; P D Walson; S E Salmon
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

View more
  14 in total

1.  The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.

Authors:  U Loos; E Musch; M Engel; J H Hartlapp; E Hügl; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma.

Authors:  H K Osterheld; E Musch; G E von Unruh; U Loos; H Rauschecker; B J Mühlenbruch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors.

Authors:  P E Noker; L Simpson-Herren; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Melphalan concentration dependent plasma protein binding in healthy humans and rats.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Pharmacokinetics of melphalan in children following high-dose intravenous injection.

Authors:  I A Taha; R A Ahmad; D W Rogers; J Pritchard; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Renal function in the elimination of oral melphalan in patients with multiple myeloma.

Authors:  C G Adair; J M Bridges; Z R Desai
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 7.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Variability of tumor response to chemotherapy. I. Contribution of host heterogeneity.

Authors:  L Simpson-Herren; P E Noker; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards.

Authors:  F Y Lee; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  The effect of systemic hyperthermia on melphalan pharmacokinetics in mice.

Authors:  D J Honess; J Donaldson; P Workman; N M Bleehen
Journal:  Br J Cancer       Date:  1985-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.